hotspot -WSS

hotspot

author：hotspot 2025-10-02 01:07:20 - browse：2

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Ionis has late

entertainment

WSS

STAT Virtual Event: How to Increase Diversity in Clinical Trials

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Health tech startups drop sharply from 2021 highs

Sudafed saga points to U.S. issues with evaluating older drugs

Intercept Pharmaceuticals sells itself for less than $1 billion

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

hotspot

hotspot

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Medicaid, Medicare dual

Guidelines to prevent youth baseball injuries need more muscle

Did you have Obamacare on your GOP debate bingo card?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Shifting the focus from loneliness to social health

How to save PrEP access — and even expand it

Menendez indictment could see pharma lose a key ally

What does generative AI mean for health care? We asked experts

Did you have Obamacare on your GOP debate bingo card?

explore

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

FDA seeks to regulate lab

How one patient went off dialysis — and others can too

Intercept Pharmaceuticals sells itself for less than $1 billion

Medicare drug price negotiation program allowed for now

Biogen shutters digital health group, ends Apple study, in cost cutting move

entertainment

entertainment

Wikipedia

Wikipedia